We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers have a long way to go when it comes to fulfilling their required postmarket reporting, according to the FDA’s most recent numbers. Read More
The European Medicines Agency (EMA) is requesting public comment on its new multi-stakeholder platform, Accelerating Clinical Trials (ACT) EU, for improving clinical trials within the trade bloc. Read More
Sage Therapeutics and Biogen announced Monday that the FDA has given priority review to the companies’ new drug application (NDA) for zuranolone for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Read More
In a case with wide-ranging implications for how broad patent protections can be, Sanofi and Regeneron are calling on the Supreme Court to deny Amgen’s attempt to overturn an appeals court’s rejection of Amgen’s patent for its blockbuster cholesterol treatment Repatha (evolocumab). Read More
More than two years after receiving an FDA rejection, Mesoblast has resubmitted its biologics license application (BLA) for remestemcel-L, a treatment for children afflicted with steroid-refractory acute graft vs. host disease (SR-aGVHD). Read More
The FDA has warned consumers not to use EzriCare Artificial Tears or Delsam Pharma’s Artificial Tears due to potential bacterial contamination that has caused permanent vision loss from eye infections and one death. Read More
As the Biden administration prepares to end the COVID-19 public health emergency on May 11, the FDA must decide what to do with dozens of temporary guidances issued during the public health emergency. Read More